Tarsus Historical Balance Sheet

TARS Stock

USD 51.68 1.03 2.03%

Trend analysis of Tarsus Pharmaceuticals balance sheet accounts such as Net Tangible Assets of 114 M, Property Plant And Equipment Net of 1.7 M, Accounts Payable of 29.1 M or Cash of 124.3 M provides information on Tarsus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Tarsus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Tarsus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Tarsus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tarsus Pharmaceuticals is a good buy for the upcoming year.

Tarsus Pharmaceuticals Inventory

2.49 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.

About Tarsus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Tarsus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Tarsus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Tarsus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Tarsus currently owns. An asset can also be divided into two categories, current and non-current.

Tarsus Pharmaceuticals Balance Sheet Chart

At this time, Tarsus Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 613.8 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 147.7 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Total Assets

Total assets refers to the total amount of Tarsus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tarsus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Tarsus Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Tarsus Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Tarsus Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Tarsus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.At this time, Tarsus Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 613.8 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 147.7 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	9.2M	18.4M	52.3M	54.9M
Total Assets	227.9M	265.5M	377.0M	201.4M

Other Current Liab Total Assets

Tarsus Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment
Total Assets		0.77	0.8	0.97	0.96	0.96	-0.57	-0.86	0.81	0.8	0.78	0.99	0.72	0.98	0.97	0.63	0.87	0.92	0.75	0.99	0.85	1.0	0.99	0.99	0.99	0.93
Other Current Liab	0.77		1.0	0.68	0.62	0.72	-0.1	-0.97	0.98	0.48	1.0	0.73	0.99	0.66	0.75	0.82	0.95	0.93	0.95	0.73	0.92	0.77	0.73	0.73	0.73	0.59
Total Current Liabilities	0.8	1.0		0.7	0.65	0.76	-0.14	-0.98	0.99	0.52	1.0	0.75	0.99	0.69	0.77	0.82	0.96	0.94	0.96	0.75	0.94	0.79	0.75	0.75	0.75	0.62
Total Stockholder Equity	0.97	0.68	0.7		1.0	0.94	-0.67	-0.77	0.72	0.85	0.68	0.98	0.61	0.98	0.92	0.45	0.83	0.89	0.61	0.99	0.79	0.97	0.98	0.98	0.98	0.96
Net Tangible Assets	0.96	0.62	0.65	1.0		0.93	-0.69	-0.73	0.67	0.85	0.63	0.98	0.55	0.98	0.91	0.41	0.78	0.85	0.56	0.99	0.74	0.96	0.98	0.98	0.98	0.96
Property Plant And Equipment Net	0.96	0.72	0.76	0.94	0.93		-0.68	-0.84	0.8	0.88	0.75	0.95	0.67	0.94	0.93	0.55	0.85	0.9	0.69	0.95	0.9	0.96	0.95	0.95	0.95	0.88
Net Debt	-0.57	-0.1	-0.14	-0.67	-0.69	-0.68		0.25	-0.21	-0.92	-0.15	-0.63	-0.03	-0.66	-0.59	-0.05	-0.34	-0.41	-0.1	-0.61	-0.4	-0.58	-0.63	-0.63	-0.63	-0.73
Retained Earnings	-0.86	-0.97	-0.98	-0.77	-0.73	-0.84	0.25		-0.99	-0.6	-0.98	-0.82	-0.96	-0.77	-0.83	-0.8	-0.95	-0.97	-0.93	-0.82	-0.97	-0.85	-0.82	-0.82	-0.82	-0.68
Accounts Payable	0.81	0.98	0.99	0.72	0.67	0.8	-0.21	-0.99		0.57	0.99	0.77	0.98	0.71	0.79	0.81	0.94	0.95	0.95	0.77	0.97	0.8	0.77	0.77	0.77	0.64
Cash	0.8	0.48	0.52	0.85	0.85	0.88	-0.92	-0.6	0.57		0.52	0.83	0.42	0.84	0.81	0.37	0.67	0.73	0.47	0.81	0.72	0.8	0.83	0.84	0.83	0.87
Non Current Assets Total	0.78	1.0	1.0	0.68	0.63	0.75	-0.15	-0.98	0.99	0.52		0.74	0.99	0.67	0.76	0.82	0.95	0.93	0.96	0.74	0.94	0.77	0.73	0.73	0.73	0.6
Cash And Short Term Investments	0.99	0.73	0.75	0.98	0.98	0.95	-0.63	-0.82	0.77	0.83	0.74		0.67	1.0	0.97	0.59	0.85	0.91	0.71	0.99	0.83	1.0	1.0	1.0	1.0	0.96
Net Receivables	0.72	0.99	0.99	0.61	0.55	0.67	-0.03	-0.96	0.98	0.42	0.99	0.67		0.6	0.7	0.83	0.91	0.89	0.96	0.67	0.91	0.71	0.66	0.66	0.66	0.53
Common Stock Total Equity	0.98	0.66	0.69	0.98	0.98	0.94	-0.66	-0.77	0.71	0.84	0.67	1.0	0.6		0.96	0.54	0.8	0.87	0.65	0.99	0.78	0.99	1.0	1.0	1.0	0.96
Common Stock Shares Outstanding	0.97	0.75	0.77	0.92	0.91	0.93	-0.59	-0.83	0.79	0.81	0.76	0.97	0.7	0.96		0.73	0.84	0.89	0.79	0.94	0.84	0.98	0.97	0.97	0.97	0.92
Non Current Liabilities Total	0.63	0.82	0.82	0.45	0.41	0.55	-0.05	-0.8	0.81	0.37	0.82	0.59	0.83	0.54	0.73		0.73	0.72	0.95	0.51	0.75	0.62	0.59	0.59	0.59	0.46
Other Current Assets	0.87	0.95	0.96	0.83	0.78	0.85	-0.34	-0.95	0.94	0.67	0.95	0.85	0.91	0.8	0.84	0.73		0.97	0.89	0.85	0.95	0.87	0.85	0.85	0.85	0.73
Other Stockholder Equity	0.92	0.93	0.94	0.89	0.85	0.9	-0.41	-0.97	0.95	0.73	0.93	0.91	0.89	0.87	0.89	0.72	0.97		0.87	0.91	0.96	0.92	0.91	0.91	0.91	0.82
Total Liab	0.75	0.95	0.96	0.61	0.56	0.69	-0.1	-0.93	0.95	0.47	0.96	0.71	0.96	0.65	0.79	0.95	0.89	0.87		0.67	0.89	0.74	0.7	0.7	0.7	0.57
Net Invested Capital	0.99	0.73	0.75	0.99	0.99	0.95	-0.61	-0.82	0.77	0.81	0.74	0.99	0.67	0.99	0.94	0.51	0.85	0.91	0.67		0.82	0.99	0.99	0.99	0.99	0.95
Property Plant And Equipment Gross	0.85	0.92	0.94	0.79	0.74	0.9	-0.4	-0.97	0.97	0.72	0.94	0.83	0.91	0.78	0.84	0.75	0.95	0.96	0.89	0.82		0.85	0.82	0.82	0.82	0.7
Total Current Assets	1.0	0.77	0.79	0.97	0.96	0.96	-0.58	-0.85	0.8	0.8	0.77	1.0	0.71	0.99	0.98	0.62	0.87	0.92	0.74	0.99	0.85		0.99	0.99	0.99	0.94
Capital Stock	0.99	0.73	0.75	0.98	0.98	0.95	-0.63	-0.82	0.77	0.83	0.73	1.0	0.66	1.0	0.97	0.59	0.85	0.91	0.7	0.99	0.82	0.99		1.0	1.0	0.96
Net Working Capital	0.99	0.73	0.75	0.98	0.98	0.95	-0.63	-0.82	0.77	0.84	0.73	1.0	0.66	1.0	0.97	0.59	0.85	0.91	0.7	0.99	0.82	0.99	1.0		1.0	0.96
Common Stock	0.99	0.73	0.75	0.98	0.98	0.95	-0.63	-0.82	0.77	0.83	0.73	1.0	0.66	1.0	0.97	0.59	0.85	0.91	0.7	0.99	0.82	0.99	1.0	1.0		0.96
Property Plant Equipment	0.93	0.59	0.62	0.96	0.96	0.88	-0.73	-0.68	0.64	0.87	0.6	0.96	0.53	0.96	0.92	0.46	0.73	0.82	0.57	0.95	0.7	0.94	0.96	0.96	0.96

Click cells to compare fundamentals

Tarsus Pharmaceuticals Account Relationship Matchups

Tarsus Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	172.0M	178.9M	227.9M	265.5M	377.0M	201.4M
Other Current Liab	2.9M	7.3M	9.2M	18.4M	52.3M	54.9M
Total Current Liabilities	5.4M	11.5M	15.4M	36.9M	80.6M	84.6M
Total Stockholder Equity	166.0M	166.7M	192.9M	197.0M	224.5M	147.7M
Net Tangible Assets	(6.0M)	166.0M	166.7M	192.9M	221.8M	114.0M
Property Plant And Equipment Net	1.2M	1.8M	1.5M	3.3M	2.9M	1.7M
Net Debt	(167.3M)	(169.4M)	(51.5M)	(193.2M)	(22.4M)	(23.5M)
Retained Earnings	(32.8M)	(46.7M)	(108.8M)	(244.7M)	(360.2M)	(342.2M)
Accounts Payable	2.2M	2.9M	5.5M	18.1M	27.7M	29.1M
Cash	168.1M	171.3M	71.7M	224.9M	94.8M	124.3M
Non Current Assets Total	1.3M	3.0M	2.5M	9.4M	20.3M	21.3M
Cash And Short Term Investments	168.1M	171.8M	217.0M	227.4M	291.4M	178.5M
Net Receivables	20K	92K	3.6M	17.7M	48.1M	50.5M
Common Stock Shares Outstanding	20.3M	20.6M	24.6M	29.4M	37.6M	24.6M
Liabilities And Stockholders Equity	172.0M	178.9M	227.9M	265.5M	377.0M	201.4M
Non Current Liabilities Total	605K	699K	19.5M	31.6M	71.8M	75.4M
Capital Lease Obligations	831K	1.9M	773K	398K	608K	733.1K
Other Current Assets	2.5M	8.1M	4.8M	7.9M	14.7M	15.4M
Other Stockholder Equity	198.8M	213.4M	301.7M	441.6M	584.6M	613.8M
Total Liab	6.0M	12.2M	35.0M	68.5M	152.5M	160.1M
Net Invested Capital	166.0M	166.7M	212.3M	226.8M	296.4M	166.7M
Property Plant And Equipment Gross	548K	1.8M	957K	4.6M	4.8M	5.1M
Total Current Assets	170.7M	176.0M	225.4M	256.1M	356.7M	195.7M
Accumulated Other Comprehensive Income	(63.4M)	(172.0M)	(74K)	(2K)	179K	188.0K
Net Working Capital	165.3M	164.5M	209.9M	219.2M	276.1M	172.0M
Property Plant Equipment	280K	1.2M	755K	957K	1.1M	711.5K
Short Long Term Debt Total	831K	1.9M	20.2M	31.7M	72.5M	76.1M
Non Currrent Assets Other	81K	463K	585K	1.5M	6.1M	6.4M
Other Assets	769K	178.9K	477K	1.0	0.9	0.86
Short Term Debt	282K	1.3M	721K	398K	608K	619.5K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tarsus Historical Balance Sheet

Tarsus Pharmaceuticals Inventory

2.49 Million

About Tarsus Balance Sheet Analysis

Tarsus Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Tarsus Pharmaceuticals balance sheet Correlations

Tarsus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tarsus Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Tarsus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Non Current Assets Total	+ 1.0	Other Current Liab
Non Current Assets Total	+ 1.0	Total Current Liabilities
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Common Stock Total Equity	+ 1.0	Cash And Short Term Investments

Accounts Payable	- 0.99	Retained Earnings
Non Current Assets Total	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Property Plant And Equipment Gross	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab